H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CDNA stock, giving a Hold rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen’s rating is based on several factors impacting CareDx’s financial outlook. The company reported a decline in revenue for the second quarter of 2025, missing projections and showing a year-over-year decrease. Although the adjusted revenue was in line with expectations, the net loss exceeded estimates, indicating financial challenges.
Additionally, while there are positive developments like the launch of AlloSure Plus and increased testing volume, uncertainties remain due to a draft Local Coverage Determination (LCD) by MolDX. This draft policy could potentially affect the company’s long-term prospects, with possible financial headwinds depending on its final implementation. These mixed signals contribute to the Hold rating, reflecting caution amid both opportunities and risks.
In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $14.50 price target.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CDNA in relation to earlier this year.